

approaches to block HIV transmission and to treat infected people. A small animal expressing both human CCR5 along with human CD4 supports entry of HIV into target cells, a necessary hurdle that must be overcome for development of a small animal model (e.g. transgenic mouse, rat, rabbit, mink) to study HIV infection and its inhibition.

The invention embodies the CCR5 genetic sequence, cell lines and transgenic animals, the cells of which coexpress human CD4 and CCR5, and which may represent valuable tools for the study of HIV infection and for screening anti-HIV agents. The invention also embodies anti-CCR5 agents that block HIV env-mediated membrane fusion associated with HIV entry into human CD4-positive target cells or between HIV-infected cells and uninfected human CD4-positive target cells.

**Inventors:** Christophe Combadiere, Yu Feng, Ghalib Alkhatib, Edward A. Berger, Philip M. Murphy, Christopher C. Broder, Paul E. Kennedy (NIAID).

**Publication:** This technology was reported in Alkhatib *et al.*, "CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1," *Science* 1996 Jun 28;272(5270):1955-1958.

**Patent Status:**

- U.S. Provisional Application No. 60/018,508 filed 28 May 1996 (HHS Reference No. E-090-1996/0-US-01)
- U.S. Patent Application No. 08/864,458 filed 28 May 1997 (HHS Reference No. E-090-1996/0-US-04)
- U.S. Patent No. 7,151,087 issued 19 Dec 2006 (HHS Reference No. E-090-1996/0-US-06)
- U.S. Patent Application No. 10/439,845 filed 15 May 2003 (HHS Reference No. E-090-1996/0-US-05)
- U.S. Patent Application No. 10/846,185 filed 14 May 2004 (HHS Reference No. E-090-1996/0-US-07)
- U.S. Patent Application No. 11/594,375 filed 07 Nov 2006 (HHS Reference No. E-090-1996/0-US-08)
- PCT Application No. PCT/US97/09586 filed 28 May 1997 (HHS Reference No. E-090-1996/0-PCT-02)
- European Patent Application No. 97929777.7 filed 28 May 1997 (HHS Reference No. E-090-1996/0-EP-03)

**Licensing Status:** The technology is available for exclusive or nonexclusive licensing.

**Licensing Contact:** Peter Soukas; 301/435-4646; [soukasp@mail.nih.gov](mailto:soukasp@mail.nih.gov).

**Collaborative Research Opportunity:** The NIAID Laboratory of Molecular Immunology and Laboratory of Viral Diseases are seeking statements of

capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize CCR5-related products. Please contact Philip Murphy (301-496-8616, [pmm@nih.gov](mailto:pmm@nih.gov)) or Edward Berger (301-402-2481, [edward\\_berger@nih.gov](mailto:edward_berger@nih.gov)) for more information.

Dated: June 11, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7-11854 Filed 6-19-07; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes on Health

#### National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, Special Review.

**Date:** June 28, 2007.

**Time:** 1:30 p.m. to 3:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call).

**Contact Person:** Kesinee Nimit, MD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 435-1432.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, Pathway to Independence Award.

**Date:** July 11, 2007.

**Time:** 1 p.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call).

**Contact Person:** Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 402-6626. [gm145a@nih.gov](mailto:gm145a@nih.gov).

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel, NIDA-K Conflicts.

**Date:** July 17, 2007.

**Time:** 5 p.m. to 6 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Doubletree Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

**Contact Person:** Mark Swieter, PhD, Chief, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Suite 220, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 435-1389. [ms80x@nih.gov](mailto:ms80x@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS).

Dated: June 13, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-3012 Filed 6-19-07; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel, T-Cell Immunology.

**Date:** July 10, 2007.

**Time:** 11 a.m. to 3 p.m.

**Agenda:** To review and evaluate grant applications.